# Daniel Morgensztern

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/daniel-morgensztern/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,067 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 51 |
| i10-index | 141 |
| Last Known Institution | Barnes-Jewish Hospital |
| OpenAlex ID | https://openalex.org/A5031420337 |
| ORCID iD | https://orcid.org/0000-0003-4349-2028 |
| Works | 462 |

## Researcher papers

- [Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database](https://scholariq.org/papers/changing-epidemiology-of-small-cell-lung-cancer-in-the-united-states-over-the/)
- [Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/non-small-cell-lung-cancer-version-3-2022-nccn-clinical-practice-guidelines-in/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-2-2021/)
- [Non–Small Cell Lung Cancer, Version 4.2024](https://scholariq.org/papers/non-small-cell-lung-cancer-version-4-2024/)
- [Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study](https://scholariq.org/papers/rovalpituzumab-tesirine-a-dll3-targeted-antibody-drug-conjugate-in-recurrent/)
- [NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-2-2023/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Barnes-Jewish Hospital](https://scholariq.org/institutions/barnes-jewish-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.